Literature DB >> 19370784

Non-alcoholic steatohepatitis with normal aminotransferase values.

Hüseyin Saadettin Uslusoy1, Selim Giray Nak, Macit Gülten, Zeynep Biyikli.   

Abstract

AIM: To investigate the aspects of liver histology in patients with non-alcoholic steatohepatitis (NASH) who had normal aminotransferase levels.
METHODS: Thirty-four patients diagnosed with liver steatosis by ultrasonographic examination participated in the study. We compared all non-alcoholic fatty liver disease and NASH cases, according to aminotransferase level, aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio and presence of metabolic syndrome.
RESULTS: Sixteen of 25 patients with high aminotransferase levels were diagnosed with NASH and nine with simple fatty liver according to liver histology. Among the nine patients with normal aminotransferase levels, seven had NASH and two had simple fatty liver. The patients with normal and high liver enzyme levels had almost the same prevalence of NASH and metabolic syndrome. Liver histology did not reveal any difference according to aminotransferase levels and AST/ALT ratio.
CONCLUSION: Aminotransferase levels and AST/ALT ratio do not seem to be reliable predictors for NASH. Despite numerous non-invasive biomarkers, all patients with fatty liver should undergo liver biopsy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19370784      PMCID: PMC2670414          DOI: 10.3748/wjg.15.1863

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  20 in total

1.  Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults.

Authors:  Chien-Hua Chen; Min-Ho Huang; Jee-Chun Yang; Chiu-Kue Nien; Chi-Chieh Yang; Yung-Hsiang Yeh; Sen-Kou Yueh
Journal:  J Clin Gastroenterol       Date:  2006-09       Impact factor: 3.062

Review 2.  Non-alcoholic steatohepatitis and metabolic syndrome.

Authors:  Mariana Machado; Helena Cortez-Pinto
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2006-09       Impact factor: 4.294

Review 3.  Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy.

Authors:  Giada Sebastiani; Alfredo Alberti
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

4.  Clinical spectrum and natural history of non-alcoholic steatohepatitis with normal alanine aminotransferase values.

Authors:  Deepak N Amarapurkar; Nikhil D Patel
Journal:  Trop Gastroenterol       Date:  2004 Jul-Sep

5.  Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women.

Authors:  Sachin S Kunde; Audrey J Lazenby; Ronald H Clements; Gary A Abrams
Journal:  Hepatology       Date:  2005-09       Impact factor: 17.425

6.  Silent non-alcoholic fatty liver disease-a clinical-histological study.

Authors:  Paolo Sorrentino; Giovanni Tarantino; Paolo Conca; Alessandro Perrella; Maria Luigi Terracciano; Raffaella Vecchione; Giovanna Gargiulo; Nicola Gennarelli; Roberto Lobello
Journal:  J Hepatol       Date:  2004-11       Impact factor: 25.083

7.  High prevalence of metabolic complications in patients with non-alcoholic fatty liver disease.

Authors:  I Friis-Liby; F Aldenborg; P Jerlstad; K Rundström; E Björnsson
Journal:  Scand J Gastroenterol       Date:  2004-09       Impact factor: 2.423

Review 8.  Nonalcoholic fatty liver disease.

Authors:  Paul Angulo
Journal:  Rev Gastroenterol Mex       Date:  2005-11

9.  Nonalcoholic steatohepatitis (NASH) with diabetes: predictors of liver fibrosis.

Authors:  D N Amarapurka; A D Amarapurkar; N D Patel; S Agal; R Baigal; P Gupte; S Pramanik
Journal:  Ann Hepatol       Date:  2006 Jan-Mar       Impact factor: 2.400

10.  Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.

Authors:  J Ludwig; T R Viggiano; D B McGill; B J Oh
Journal:  Mayo Clin Proc       Date:  1980-07       Impact factor: 7.616

View more
  19 in total

Review 1.  Drug metabolism alterations in nonalcoholic fatty liver disease.

Authors:  Matthew D Merrell; Nathan J Cherrington
Journal:  Drug Metab Rev       Date:  2011-05-25       Impact factor: 4.518

Review 2.  The de ritis ratio: the test of time.

Authors:  Mona Botros; Kenneth A Sikaris
Journal:  Clin Biochem Rev       Date:  2013-11

Review 3.  Implications of Nonalcoholic Steatohepatitis as the Cause of End-Stage Liver Disease Before and After Liver Transplant.

Authors:  Anchalia Chandrakumaran; Mohammad Shadab Siddiqui
Journal:  Gastroenterol Clin North Am       Date:  2020-03       Impact factor: 3.806

4.  Current status and agenda in the diagnosis of nonalcoholic steatohepatitis in Japan.

Authors:  Yoshio Sumida; Yuichiro Eguchi; Masafumi Ono
Journal:  World J Hepatol       Date:  2010-10-27

5.  Active p38α causes macrovesicular fatty liver in mice.

Authors:  Ilona Darlyuk-Saadon; Chen Bai; Chew Kiat Matthew Heng; Nechama Gilad; Wei-Ping Yu; Pei Yen Lim; Amaury Cazenave-Gassiot; Yongliang Zhang; W S Fred Wong; David Engelberg
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-06       Impact factor: 11.205

6.  Targeted hepatic sonography during clinic visits for detection of fatty liver in overweight children: a pilot study.

Authors:  Emily R Perito; Patrika M Tsai; Sarah Hawley; Robert H Lustig; Vickie A Feldstein
Journal:  J Ultrasound Med       Date:  2013-04       Impact factor: 2.153

7.  Biomarkers for noninvasive biochemical diagnosis of nonalcoholic steatohepatitis: tools or decorations?

Authors:  Yusuf Yilmaz; Enver Dolar
Journal:  World J Gastroenterol       Date:  2009-09-14       Impact factor: 5.742

8.  Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population.

Authors:  Yoshio Sumida; Masato Yoneda; Hideyuki Hyogo; Yoshito Itoh; Masafumi Ono; Hideki Fujii; Yuichiro Eguchi; Yasuaki Suzuki; Noriaki Aoki; Kazuyuki Kanemasa; Koji Fujita; Kazuaki Chayama; Toshiji Saibara; Norifumi Kawada; Kazuma Fujimoto; Yutaka Kohgo; Toshikazu Yoshikawa; Takeshi Okanoue
Journal:  BMC Gastroenterol       Date:  2012-01-05       Impact factor: 3.067

9.  Individual CLA Isomers, c9t11 and t10c12, Prevent Excess Liver Glycogen Storage and Inhibit Lipogenic Genes Expression Induced by High-Fructose Diet in Rats.

Authors:  Edyta Maslak; Elzbieta Buczek; Antoni Szumny; Wojciech Szczepnski; Magdalena Franczyk-Zarow; Aneta Kopec; Stefan Chlopicki; Teresa Leszczynska; Renata B Kostogrys
Journal:  Biomed Res Int       Date:  2015-05-18       Impact factor: 3.411

10.  The hepatoprotective and hypolipidemic effects of Spirulina (Arthrospira platensis) supplementation in a Cretan population with non-alcoholic fatty liver disease: a prospective pilot study.

Authors:  Elias E Mazokopakis; Maria G Papadomanolaki; Andreas A Fousteris; Dimitrios A Kotsiris; Ioannis M Lampadakis; Emmanuel S Ganotakis
Journal:  Ann Gastroenterol       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.